CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...